Acellular antibordetella vaccine

Details Acellular antibordetella vaccine Acellular antibordetella vaccine

2005-09-20

2008-12-16

Minnifield, N. M (Department: 1645)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Bacteria or actinomycetales

C424S093300, C424S093200, C424S253100, C424S254100, C424S282100, C424S234100, C435S071100, C435S071200, C435S071300, C435S261000, C435S308100

Reexamination Certificate

active

07465443

ABSTRACT:
The invention relates to an immunogenic composition, characterized in that it comprises an adenyl cyclase-hemolysin (AC-Hly) protein, or an immunogenic portion of this AC-Hly, of a strain ofBordetellachosen fromB. pertussis, B. parapertussisorB. bronchiseptica,and in that it comprises, in addition, a bacterial extract containing the expression products of the vrg genes of a strain ofBordetellachosen fromB. pertussis, B. parapertussisorB. bronchiseptica,or a portion of these expression products which is sufficient to induce an immune response in a host to which the extract might be administered.

REFERENCES:
patent: 5095094 (1992-03-01), Brezin et al.
patent: 5183745 (1993-02-01), Danchin et al.
patent: 5595901 (1997-01-01), Rocancourt et al.
patent: 6030625 (2000-02-01), Guierard et al.
patent: 6309648 (2001-10-01), Betsou et al.
patent: 6387377 (2002-05-01), Guierard et al.
patent: 6994854 (2006-02-01), Betsou et al.
patent: 7105317 (2006-09-01), Gueirard et al.
patent: 2006/0073169 (2006-04-01), Gueirard et al.
patent: 2006/0292161 (2006-12-01), Betsou et al.
patent: 162 639 (1985-11-01), None
patent: 0338 170 (1989-10-01), None
patent: 2 606 789 (1988-05-01), None
patent: WO 90/13312 (1990-11-01), None
Fernandez et al, Abstract ASM Meeting 2002, 102:174 abstract only.
Stenson et al, Infection and Immunity, Sep. 2005, 73/9:5995-6004.
Akerely et al., “ThebvgASLocus Negatively Controls Motility and Synthesis of Flagella inBordetalla bronchiseptica”, J. Bacteriology174(3):980-990 (Feb. 1992).
Bartoloni et al., Engineering Bacterial Toxin for the Development of New Vaccine against Pertussis,Tokai J. Exp. Clin. Med. 13(Suppl):217-22 (1988).
Beattie et al., “Evidence that Modulation Requires Sequences Downstream of the Promoters of Two vir-Repressed Genes ofBordetella pertussis”, J. Bacteriol. 172(12):6997-7004 (1990).
Beattie et al., “Repressor Binding to a Regulatory Site in the DNA Coding Sequence Is Sufficient To Confer Transcriptional Regulation of the vir-Repressed Genes (vrg Genes) InBordetella pertussis”, J. Bacteriol. 175(2):519-527 (1993).
Beattie et al., “Avir-Repressed Gene ofBordetella pertussisIs Required for Virulence”,Infection and Immunity60(2):571-577 (1992).
Betsou et al., “CyaC-Medicated Activation is Important Not Only for Toxic but Also for Protective Activities ofBordetella pertusisAdenylate Cyclase-Hemolysin”,Infection and Immunity61(9):3583-3589 (1993).
Betsou et al., “Cloning and sequence of theBordetella bronchisepticaadenylate cyclase-hemolysin-encoding gene: comparison with theBordetella pertussisgene”, Gene 162:165-166 (1995).
Brennan et al., “Identification of a 69 -Kilodalton Nonfrimbrial Protein As an Agglutinogen ofBordetella pertussis”, Infection and Immunity56(12):3189-3195 (Dec. 1998).
Charles et al., “Molecular cloning and characterization of protective outer membrane protein p. 69 fromBordetella pertussis”, Proc. Natl. Acad. Sci. USA 86:3554-3558 (May 1989).
Charles, et al., “Molecular Cloning and Analysis of p. 69, avir-controlled Protein fromBordetella pertussis”, Tokai J. Exp. Clin. Med. 13:227-234 (1988).
Endoh et al., “Adenylate Cyclase Activity ofBordetellaOrganisms”,Microbio. Immunol24(2):95-104 (1980).
Friedman, “Bordetella pertussisAdenylate Cyclase; Isolation and Purification by Calmodulin-Sepharose 4B Chromatography”,Infection and Immunity55(1):129-134 (Jan. 1987).
Goldman et al., “Spontaneous phase variation inBordetella pertussisis a multistep non-random process”,EMBO Journal3(6):1353-1356 (1984).
Grimprel et al., “Long-Term Human Serum Antibody Responses after Immunization with Whole-Cell Pertussis Vaccine in France”,Clinical&Diagnostic Laboratory Immunology3(1):93-97 (1996).
Gross et al., “Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyA toxin ofBordetella pertussisabolish virulence”,Proc. Natl. Acad. Sci. USA 89:4898-4902 (1992).
Guierrard et al., “Intranasal Inoculation ofBordetella bronchisepticain Mice Induces Long-Lasting Antibody and T-Cell Mediated Immune Responses”,Scand. J. Immunol., 43:181-192 (1996).
Gueirard et al., “HumanBordetella bronchispeticaInfection Related to Contact with Infected Animals: Persistence of Bacteria in Host”,J. Clin. Microbiol. 33(8):2002-2006 (1995).
Guierard et al., “Virulence ofBordetella bronchiseptica: Role of Adenylate Cyclase-Hemolysin”,Infection&Immunity61(10):4072-4078 (1993).
Guierard et al., “Virulence ofBordetella bronchiseptica”, inBacterialProtein Toxins, ed. Freer et al., Suppl. 24:152-153 (1994).
Glaser et al., “the calmodulin-sensitive adenylate cylase ofBordetella pertussis: cloning and expression inEscherichia coli”, Molecular Microbiology2(1):19-30 (1998).
Gulso et al., “Murine Models to StudyBordetellaPathogenesis and to Characterize Protective Antigens”, in Bacterial Protein toxins, Zentralblatt fur Bakteriologie International,J. of Med. Microbiology, Suppl. 23:263-271 (1992).
Guiso et al., “Protective activity ofBordetellaadenylate cyclase-hemolysin against bacterial colonization”,Microbial Pathogenesis11:423-431 (1991).
Hackett et al., “Hemolytic, but Not Cell-Invasive Activity, of Adenylate Cyclase Toxin Is Selectively Affected by Differential Fatty-acylation inEscherichia coli”, The Journal of Biological Chemistry270(35):20250-20253 (Sep. 1995).
Hackett et al., “Internal Lysine Palmitoylation in Adenylate Cyclase Toxin fromBordetella pertussis”, Science266:433-435 (1994).
Hail et al., “Repression of adenylate cyclase in the genusBordetella”, Microbios33:45-52 (1982).
Hausman et al., “analysis of Proteins Encloded by the ptx and ptl Genes ofBordetella bronchisepticaandBordetella parapertussis”, Infection and Immunity64(10):4020-4026 (1996).
Hewlett et al., “Adenylate Cyclase Toxin fromBordetella pertussis: Identification and Purification of the Holotoxin Molecule”,The Journal of Biological Chemistry264(32):19379-19384 (Nov. 1989).
Hewlett et al., “Extracytoplasmic adenylate cyclase ofBordetella pertussis” Proc. Natl. Acad. Sci. USA 73(6): 1929-30 (1976).
Horiguchi et al., “Effects ofBordetella bronchisepticaDermonecrotic Toxin on the Structure and Function of Osteoblastic Clone MC3T3-E1 Cells”,Infection&Immunity59(3):1112-1116 (1991).
Iwaki et al., “Identification byin vitrocomplementation of regions required for cell-invasive activity ofBordetella pertussisadenylate cyclase toxin”,Molecular Microbiology17(6):1015-1024 (1995).
Kessin et al., “Secreted Adenylate Cyclase ofBordetella pertussis: Calmodulin Requirements and Partial Purification of Two forms”,Journal of Bacteriology166(1):290-296 (1986).
Khelef et al., “Characterization of Murine Lung Inflammation after Infection with ParentalBordetella pertussisand Murtnats Deficient in Adhesions of Toxins”,Infection and Immunity62(7):2893-2900 (1994).
Khelef et al., “BordetellaSpecies are Immunologically Different”, Bacterial Protein Toxins ed. Freer et al., Suppl. 24:514-515 (1994).
Khelef et al., “Bordetella pertussisandBordetella parapertussis: two immunologically distinct species”,Infection&Immunity61(2):486-490 (1993).
Khelef et al., “Both adenylate cyclase and hemolytic activities are required byBordetella pertussisto initiate infection”,Microbial Pathogenesis12:227-235 (1992).
Knapp et al., “Two trans-Acting Regulatory Genes (virandmod) Control Antigenic Modulation inBordetella pertussis”, J. Bacteriol170(11):5059-5066 (1988).
Lacey et al., “Antigenic modulation ofBordetella pertussis”, J. of Hygiene Camb. 58:57-93 (1960).
Ladant et al., “Bordetella pertussisAdenylate Cyclase: Purification, Characterization and Radioimmunoassay”,The

Affiliated with

Also associated with

Rating

Acellular antibordetella vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acellular antibordetella vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acellular antibordetella vaccine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4043789